- $34.23m
- -$184.22m
- 27
- 54
- 75
- 50
Annual balance sheet for LianBio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 43.3 | 254 | 383 | 302 |
| Net Total Receivables | 0.047 | 21.3 | 7.22 | 4.41 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 43.3 | 277 | 400 | 313 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 0.532 | 2.53 | 6.64 | 7.09 |
| Other Long Term Assets | ||||
| Total Assets | 43.9 | 279 | 426 | 320 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 3.35 | 6.23 | 15.1 | 23.6 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Minority Interest | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 4.69 | 62.3 | 72.8 | 60.1 |
| Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | 39.2 | 217 | 354 | 260 |
| Total Liabilities & Shareholders' Equity | 43.9 | 279 | 426 | 320 |
| Total Common Shares Outstanding |